HOOKIPA Pharma Inc.
$84 Million - Initial Public OfferingJoint Bookrunner
Turning Point Therapeutics, Inc.
$191 Million - Initial Public OfferingJoint Bookrunner
Rocket Pharmaceuticals, Inc.
$91 Million - Follow-OnJoint Bookrunner
Biotechnology/Takeaways from the SVB Leerink GHC Immuno-Oncology Panel
Biotechnology/MEDACorp Hemophilia Survey Highlights Unmet Need For Next-Gen Disruptor Agents
HCIT / Shift to Value “Stronger than Ever” According to KLAS; MDRX Still Challenged